mir-1-mediated paracrine effect of cancer-associated fibroblasts on lung cancer cell proliferation and chemoresistance.

Lung cancer is the leading cause of cancer-related mortality in humans worldwide. Moreover, the overall 5-year survival rate is only 15%. Pathologically almost 80% of all lung cancer cases are non-small cell lung cancer (NSCLC). Cancer-associated fibroblasts (CAFs) have been found to exist in a large number of NSCLCs. CAFs have been proven to promote tumor progression, metastasis and resistance to therapy through paracrine effects in most solid tumors. In the present study, firstly we isolated CAFs from patient tissues and demonstrated that they promoted cell proliferation and chemoresistance to cisplatin in the lung cancer cell lines A549 and 95D in a paracrine manner. Secondly, using ELISA and quantative PCR, we found that a higher amount of stromal cell-derived factor 1 (SDF-1) existed in the CAFs rather than that observed in the normal fibroblasts (NFs). Thirdly, we detected that SDF-1 facilitated lung cancer cell proliferation and drug resistance via the CXCR4-mediated signaling pathway which involved NF-κB and Bcl-xL. Moreover, we also confirmed that the expression level of SDF-1 in the CAFs was negatively regulated by microRNA mir-1 through microRNA overexpression and quantitative PCR. Overall, our data provide one explanation for the effects of CAFs on lung cancer cells. Meanwhile, our results also suggest CAFs as a potential therapeutic target in tumor treatment.

[1]  Tuan-jie Li,et al.  Cancer-associated fibroblasts in digestive tumors. , 2014, World journal of gastroenterology.

[2]  Xiaomin Dong,et al.  MicroRNA-1 in Cardiac Diseases and Cancers , 2014, The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology.

[3]  G. Che,et al.  Fibroblast phenotypes in different lung diseases , 2014, Journal of Cardiothoracic Surgery.

[4]  Zujiang Yu,et al.  Role of MicroRNA-1 in Human Cancer and Its Therapeutic Potentials , 2014, BioMed research international.

[5]  C. Croce,et al.  CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia. , 2013, The Journal of clinical investigation.

[6]  Jhingook Kim,et al.  Human lung cancer-associated fibroblasts enhance motility of non-small cell lung cancer cells in co-culture. , 2013, Anticancer research.

[7]  O. Wald,et al.  CXCR4/CXCL12 Axis in Non Small Cell Lung Cancer (NSCLC) Pathologic Roles and Therapeutic Potential , 2013, Theranostics.

[8]  E. Diamandis,et al.  Cancer-Associated Fibroblasts Drive the Progression of Metastasis through both Paracrine and Mechanical Pressure on Cancer Tissue , 2012, Molecular Cancer Research.

[9]  Jeffrey E. Green,et al.  MicroRNA regulation in cancer-associated fibroblasts , 2012, Cancer Immunology, Immunotherapy.

[10]  P. Quax,et al.  MicroRNA-126 modulates endothelial SDF-1 expression and mobilization of Sca-1(+)/Lin(-) progenitor cells in ischaemia. , 2011, Cardiovascular research.

[11]  A. Fusco,et al.  MiR-1 is a tumor suppressor in thyroid carcinogenesis targeting CCND2, CXCR4, and SDF-1alpha. , 2011, The Journal of clinical endocrinology and metabolism.

[12]  A. Magliocco,et al.  CXCR4 Overexpression Is Associated with Poor Outcome in Females Diagnosed with Stage IV Non-small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[13]  L. Buscail,et al.  The silencing of microRNA 148a production by DNA hypermethylation is an early event in pancreatic carcinogenesis. , 2010, Clinical chemistry.

[14]  Beverly A. Teicher,et al.  CXCL12 (SDF-1)/CXCR4 Pathway in Cancer , 2010, Clinical Cancer Research.

[15]  O. Franco,et al.  Cancer associated fibroblasts in cancer pathogenesis. , 2010, Seminars in cell & developmental biology.

[16]  R. Perona,et al.  Control of oncogenesis and cancer therapy resistance , 2004, British Journal of Cancer.

[17]  S. Nimmagadda,et al.  The intricate role of CXCR4 in cancer. , 2014, Advances in cancer research.

[18]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.